- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06283979
ETT MULTICENTRUM, RANDOMISERAD (1:1), KONTROLLERAD FAS 2 FÖRSÖKNING AV STIMULAN VG MED DEBRIDERING OCH ETT KUR AV SYSTEMISK ANTIBIOTIKA VS STANDARD OF CARE (SOC) FÖR BEHANDLING AV BOSTOMYELIT FÖRENADD MED IV STAGE. (BLADE OPU2)
The purpose of this trial is to assess the safety, tolerability and between-group effect size of STIMULAN VG (with debridement) and a course of systemic antibiotics to standard of care (debridement and systemic antibiotics only) for the treatment of osteomyelitis associated stage IV pressure ulcers.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The trial is an open-label, multi-center, randomized (1:1), controlled phase 2 trial in patients diagnosed with stage IV pressure ulcers.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Utökad åtkomst
Kontakter och platser
Studiekontakt
- Namn: Keira Watts, Clinical Research Director
- Telefonnummer: +44 (0) 1782 338 580
- E-post: clinicaltrials@biocomposites.com
Studera Kontakt Backup
- Namn: Daniel Roberts
- E-post: droberts@mcra.com
Studieorter
-
-
Arizona
-
Phoenix, Arizona, Förenta staterna, 85032
- Rekrytering
- Advanced Foot Care, LLC
-
Huvudutredare:
- Jaminelli Banks, DPM
-
Kontakt:
- Rajashekhar Ittedi
- Telefonnummer: (480) 863-6044
- E-post: rajaittedi123@gmail.com)
-
Kontakt:
- Krishna Sai Penumarthi
- Telefonnummer: (480) 863-6044
- E-post: kspenumarthi@axentrabio.com
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60611
- Rekrytering
- Northwestern University Feinberg School of Medicine
-
Huvudutredare:
- Robert Galiano, MD
-
Kontakt:
- Brigid Coles
- Telefonnummer: 312-503-3209
- E-post: brigid.coles@nm.org
-
Kontakt:
- Tarifa Adam
- Telefonnummer: 312-503-3209
- E-post: tarifa.adam@nm.org
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48202
- Rekrytering
- Henry Ford Hospital
-
Huvudutredare:
- Aamir Siddiqui, MD
-
Kontakt:
- Sarah Meehan
- E-post: smeehan1@hfhs.org
-
Kontakt:
- Dan Molitor
- E-post: dmolito2@hfhs.org
-
-
Mississippi
-
Jackson, Mississippi, Förenta staterna, 39216
- Rekrytering
- University of Mississippi Medical Center
-
Kontakt:
- Venkata Seerapu
- E-post: vseerapu@umc.edu
-
Kontakt:
- Laxmi Dhungel
- E-post: idhungel@umc.edu
-
Huvudutredare:
- Ian Hoppe, MD
-
-
Missouri
-
Columbia, Missouri, Förenta staterna, 65201
- Rekrytering
- Missouri Orthopaedic Institute
-
Huvudutredare:
- Brett Crist, MD
-
Kontakt:
- Andrew Monhollen
- E-post: am5hf@health.missouri.edu
-
Kontakt:
- Vicki Jones
- E-post: jonesvicki@health.missouri.edu
-
-
Nebraska
-
Omaha, Nebraska, Förenta staterna, 68198
- Rekrytering
- University of Nebraska Medical Center
-
Kontakt:
- Katie Ostlund
- E-post: katie.ostlund@unmc.edu
-
Kontakt:
- Gabriel Gauthier
- E-post: gabriel.gauthier@unmc.edu
-
Huvudutredare:
- James Willcockson, MD
-
-
New Jersey
-
Newark, New Jersey, Förenta staterna, 07103
- Rekrytering
- Rutgers New Jersey Medical School
-
Kontakt:
- Mehreen Bhatti
- E-post: mb2276@njms.rutgers.edu
-
Kontakt:
- Saharsh Patel
- E-post: ssp186@gsbs.rutgers.edu
-
Huvudutredare:
- Alex Wong, MD, FACS
-
-
New York
-
Mineola, New York, Förenta staterna, 11501
- Rekrytering
- NYU Langone Hospital - Long Island Clinical Research Center
-
Huvudutredare:
- Scott Gorenstein, MD
-
Kontakt:
- Monica Benitez
- Telefonnummer: 516 663 9582
- E-post: monica.benitez@nyulangone.org
-
Kontakt:
- Anita Farha
- Telefonnummer: 516 663 9582
- E-post: anita.farhi@nyulangone.org
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15219
- Rekrytering
- University of Pittsburgh, McGowan Institute for Regenerative Medicine
-
Kontakt:
- Urmila Gnyawali
- Telefonnummer: 412-624-5500
- E-post: usg2@pitt.edu
-
Kontakt:
- Scot King
- Telefonnummer: 412-624-5500
- E-post: scot.king@pitt.edu
-
Huvudutredare:
- Sashwati Roy, PhD, MS
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
In order to be eligible to participate in this study, subjects must meet all of the following criteria:
- Presenting with a Stage IV pressure ulcer requiring treatment of excision, bony debridement and flap coverage/primary closure.
- Operative candidate for flap surgery or primary closure.
- Presence of focal osteomyelitis as suggested by imaging to show extent of infection. Acceptable imaging techniques are Magnetic Resonance Imaging or CT scan.
- Adults ≥ 18 years in age at the time of treatment.
- Psychosocially, mentally, and physically able to fully comply with this protocol, including adhering to scheduled visits, treatment plan, completing forms, and other study procedures.
- Ability of the subject or legal authorized representative to provide voluntary, signed and dated informed consent prior to any study-related procedures.
Subjects who meet any of the following criteria will be excluded from participating in this study:
-
Reasons contributing to pressure ulcer cannot be addressed.
-
Severe immunological compromised patients as determined by the clinician.
-
Patients with diffuse or widespread pelvic osteomyelitis that is not amenable to adequate margins for debridement.
-
Patients presenting with head pressure ulcers.
-
Current or recent history (within last 2 years) of active substance abuse (e.g., recreational drugs, narcotics, or alcohol) that in the judgement of the investigator, may compromise the participant's safety/recovery or ability to follow the trial procedures.
-
Current smoker.
-
Diabetic patient with Hba1C level above 9.
-
Allergy to any component of the investigational product, such as calcium sulfate, glycopeptide antibiotics (Vancomycin), or aminoglycoside antibiotics (Gentamicin).
-
Concurrent involvement in a study of another investigational product.
-
Pregnant or planning to become pregnant during study period.
-
Flexion contractures where patient cannot passively get full extension.
-
Uncontrolled muscle spasms.
-
Unable to comply with bedrest restriction or offloading requirements
-
Unable to provide consent.
-
Fecal or urinary incontinence with contamination of the wound.
-
Lower extremity pressure ulcer location that is vascularly compromised as defined by an Ankle Brachial Index ≤ 0.7 mm Hg OR toe brachial index ≤ 0.6 mm OR toe pressure ≤ 40 mm Hg OR transcutaneous oximetry ≤ 40 mm Hg *
-
Investigator considers the participant to be clinically malnourished.
-
Any conditions with known hypercalcemia (> 10.3 mg/dl) or posing a significant risk for developing hypercalcemia (i.e., Hyperparathyroidism).
-
Investigator believes trial participation may compromise safety of the participant or trial results.
- Patients presenting with lower extremity pressure ulcers that are vascularly compromised can be rescreened followed successful revascularization
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Interventional STIMULAN VG
Ulcer bursectomy and debridement and STIMULAN VG insertion into the ulcer cavity. Flap/primary closure. Peri-operative antibiotics. |
Insertion of STIMULAN VG into the ulcer cavity prior to flap/primary closure. Standard of Care. Ulcer bursectomy, debridement and flap/primary closure. Peri-operative antibiotics. |
|
Aktiv komparator: Standard of Care (SoC)
Ulcer bursectomy, debridement and flap/primary closure. Peri-operative antibiotics. |
Standard of Care. Ulcer bursectomy, debridement and flap/primary closure. Peri-operative antibiotics. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Individual patient success and findings at the 8 week follow-up visit
Tidsram: 8 week
|
An individual patient treatment will be considered a success if there is complete wound closure and healing at the surgical site at two consecutive visits 2 weeks apart. |
8 week
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 199723
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .